R-ICE Chemotherapy with or without Autologous Transplantation for Elderly Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas.

Szczegóły
Abstrakt

Tytuł:: R-ICE Chemotherapy with or without Autologous Transplantation for Elderly Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas.
Autorzy:: Turki AT
Lamm W
Liebregts T
Dührsen U
Źródło:: Oncology research and treatment [Oncol Res Treat] 2018; Vol. 41 (9), pp. 534-538. Date of Electronic Publication: 2018 Aug 08.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Basel : S. Karger, [2014]-
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, B-Cell/*therapy
Neoplasm Recurrence, Local/*therapy
Stem Cell Transplantation/*methods
Aged ; Carboplatin/therapeutic use ; Drug Resistance, Neoplasm ; Etoposide/therapeutic use ; Female ; Humans ; Ifosfamide/therapeutic use ; Kaplan-Meier Estimate ; Lymphoma, B-Cell/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Progression-Free Survival ; Retrospective Studies ; Rituximab/therapeutic use ; Survival Rate ; Transplantation, Autologous/methods
Contributed Indexing:: Keywords: Autologous transplantation; B-cell lymphoma; Diffuse large B-cell lymphoma; Elderly patients; R-ICE; Relapse
Substance Nomenclature:: 4F4X42SYQ6 (Rituximab)
6PLQ3CP4P3 (Etoposide)
BG3F62OND5 (Carboplatin)
UM20QQM95Y (Ifosfamide)
Entry Date(s):: Date Created: 20180808 Date Completed: 20190903 Latest Revision: 20190903
Update Code:: 20240104
DOI:: 10.1159/000489717
PMID:: 30086544
: Czasopismo naukowe

Pełny tekst

For patients aged 60 years or older, the treatment of relapsed aggressive B-cell lymphomas remains challenging. The purpose of this retrospective analysis was to evaluate the results of the R-ICE (rituximab, ifosfamide, carboplatin, etoposide) protocol alone as compared to R-ICE followed by high-dose chemotherapy with autologous transplantation. The 3-year progression-free survival (PFS) and overall survival (OS) rates in 17 patients receiving R-ICE without transplantation were 32% (95% confidence interval (CI): 8.48-55.52) and 35% (95% CI: 11.48-58.52), respectively. Median PFS and OS times were 9 months (95% CI: 2-22) and 12 months (95% CI: 5-19), respectively. In 17 age-matched transplanted patients the respective survival rates were 18% (95% CI: 0.36-35.64) and 24% (95% CI: 4.4-43.6). Median PFS and OS times were 11 months (95% CI: 6-16) and 16 months (95% CI: 13-19), respectively. Thus, R-ICE alone is a reasonable treatment option for elderly patients with relapsed or refractory aggressive B-cell lymphomas.
(© 2018 S. Karger GmbH, Freiburg.)

Informacja